Can I Take Glycine with Lantus? What the Evidence Says

Why People Ask About Glycine and Lantus

Glycine is one of the most commonly purchased amino acid supplements in the United States, marketed for sleep quality, joint health, collagen production, and blood-sugar support. People taking Lantus encounter glycine in two contexts: as a standalone supplement and as a listed inactive ingredient on the Lantus pen label itself. That second fact raises immediate questions.

Glycine as a Lantus Excipient

Insulin glargine injection (Lantus) contains glycine at a concentration of approximately 3.6 mg per mL as a tonicity agent and protein stabilizer (FDA Lantus prescribing information). This trace amount is far below any pharmacologically active oral dose. It keeps the insulin molecule stable in the acidic pH 4.0 solution and has no independent metabolic effect once injected subcutaneously.

Why Patients Combine Them

Three use cases drive co-use. First, glycine at 3 g before bedtime is a popular sleep aid. Second, collagen peptide blends frequently contain 2 to 5 g of glycine per serving. Third, emerging research on glycine's insulin-sensitizing properties attracts people already managing type 2 diabetes. Each use case carries a slightly different risk profile, which the sections below address individually.

Pharmacokinetic Assessment: Does Glycine Change How Lantus Works?

No. The interaction between glycine and insulin glargine is not pharmacokinetic. Glycine is absorbed in the small intestine via active amino acid transporters, while insulin glargine forms microprecipitates in subcutaneous tissue that dissolve slowly over 20 to 26 hours. These two absorption pathways share no transporters, enzymes, or binding proteins.

No CYP Enzyme Overlap

Insulin glargine is degraded by tissue proteases, not by hepatic cytochrome P450 enzymes. Glycine metabolism proceeds through the glycine cleavage system in hepatic mitochondria. Because neither compound relies on CYP enzymes for clearance, there is no competitive inhibition or induction to consider (NIH Glycine Metabolism Overview).

Protein Binding Is Irrelevant Here

Insulin glargine binds to the insulin receptor, not to albumin or other plasma carrier proteins in a way that supplements can displace. Glycine circulates as a free amino acid. Displacement interactions, the kind seen with warfarin and NSAIDs, do not apply to this drug-supplement pair.

The clinical takeaway: glycine will not make Lantus peak earlier, last shorter, or distribute differently. No dose-separation window is pharmacokinetically justified.

Pharmacodynamic Overlap: The Real Interaction

The meaningful overlap is pharmacodynamic. Both glycine and insulin glargine lower blood glucose, and their effects can add together.

Glycine's Glucose-Lowering Mechanism

A 2004 study by Gannon and Nuttall gave 12 healthy volunteers 75 mg/kg of oral glycine (roughly 5.25 g for a 70 kg person) alongside a 25 g oral glucose load. The glycine group showed a glucose area-under-the-curve reduction of approximately 50% compared to glucose alone, with a simultaneously blunted insulin response (Gannon et al., Metabolism, 2004). The proposed mechanism involves glucagon stimulation paired with enhanced peripheral glucose disposal.

A later randomized controlled trial in 74 patients with type 2 diabetes found that 5 g of glycine three times daily for three months reduced HbA1c by 0.5% compared to placebo, alongside reduced inflammatory markers (Cruz et al., Canadian Journal of Physiology and Pharmacology, 2008).

How This Stacks with Lantus

Lantus provides a flat basal insulin level over 24 hours. It is specifically designed to suppress hepatic glucose output overnight and between meals. Glycine's glucose-lowering effect peaks within 30 to 60 minutes of oral ingestion and lasts roughly 2 to 3 hours. The overlap matters most when:

• Glycine is taken at bedtime (the same window many patients inject Lantus)
• The glycine dose exceeds 3 g
• The patient is already near their hypoglycemia threshold

At 1 to 3 g per day, the glucose-lowering effect of glycine is modest and unlikely to cause symptomatic hypoglycemia in most patients on stable Lantus doses. At 5 g three times daily (the dose used in the Cruz trial), the additive effect becomes clinically relevant and warrants closer glucose monitoring.

Glycine for Sleep: The Most Common Co-Use Scenario

The most frequent reason Lantus patients reach for glycine is sleep. Poor sleep is both a symptom and a driver of insulin resistance, creating a cycle that makes patients with type 2 diabetes especially interested in non-benzodiazepine sleep aids.

The Sleep Evidence

Inagawa and colleagues conducted a crossover trial in 11 healthy volunteers and found that 3 g of glycine taken before bedtime improved subjective sleep quality, reduced sleep onset latency, and decreased next-day fatigue compared to placebo (Inagawa et al., Sleep and Biological Rhythms, 2006). A subsequent polysomnography study by Bannai and colleagues confirmed that glycine shortened the time to reach slow-wave sleep without altering total sleep architecture (Bannai et al., Neuropsychopharmacology, 2012).

Sleep, Glucose, and Lantus Timing

The 3 g bedtime dose is low enough that the glucose-lowering contribution is small. But timing matters. If you inject Lantus at bedtime and take glycine simultaneously, you are combining the onset phase of Lantus action (first 2 to 4 hours) with glycine's brief glucose-lowering window.

For most patients on stable doses, this overlap is not dangerous. Still, patients who run fasting glucose values below 90 mg/dL or who have a history of nocturnal hypoglycemia should check a 2:00 AM glucose for the first few nights of combined bedtime use. That single precaution resolves most of the clinical uncertainty.

Glycine for Collagen: A Secondary Use Case

Collagen supplements are the second most common source of glycine exposure in this population. A standard 10 g collagen peptide serving delivers approximately 2.5 to 3 g of glycine, often combined with 1 to 1.5 g each of proline and hydroxyproline.

Clinical Relevance for Lantus Users

The glycine load from collagen supplements falls within the same 2 to 3 g range as the sleep dose. The timing, however, differs. Most people take collagen with a morning coffee or in a post-workout shake, placing the glycine peak far from the overnight Lantus window.

This timing pattern actually reduces interaction risk. A morning collagen dose delivers its glucose-lowering effect when cortisol and hepatic glucose output are naturally high, buffering against hypoglycemia. No dose adjustment to Lantus is needed for standard collagen supplementation taken in the morning.

High-Dose Glycine for Metabolic Support: Where Caution Applies

The 15 g/day regimen studied by Cruz and colleagues (5 g three times daily) is the scenario that requires the most attention from Lantus users.

The Evidence for Metabolic Benefit

The Cruz 2008 trial enrolled type 2 diabetes patients and found that 15 g/day glycine reduced fasting glucose by approximately 10%, lowered HbA1c by 0.5 percentage points, and decreased TNF-alpha and IL-6 levels over 3 months (Cruz et al., 2008). A 2018 study by Yan-Do and colleagues described glycine receptor expression on human pancreatic alpha cells, offering a mechanism by which glycine modulates glucagon secretion and downstream glucose homeostasis (Yan-Do et al., Diabetes, 2016).

Practical Risk at 15 g/day

A 0.5% HbA1c reduction is roughly equivalent to what some clinicians would achieve by adding a low-dose oral agent. When this effect stacks on top of a Lantus dose already titrated to target, the result can be fasting glucose values 10 to 20 mg/dL lower than expected. That shift can push patients below 70 mg/dL, the threshold for clinical hypoglycemia defined by the American Diabetes Association (ADA Standards of Care 2024).

Patients using 15 g/day glycine alongside Lantus should:

• Increase fingerstick or CGM monitoring frequency for the first 4 weeks
• Be prepared to reduce their Lantus dose by 10 to 20% if fasting glucose consistently falls below 80 mg/dL
• Discuss the supplement with their prescribing clinician before starting

This is not a contraindication. It is a dose-dependent interaction that becomes manageable with monitoring.

Monitoring Recommendations by Glycine Dose

The intensity of monitoring should match the glycine dose. A blanket recommendation to "talk to your doctor" is unhelpful without specifics. Here is a dose-stratified approach.

Low Dose (1 to 3 g/day)

This covers the bedtime sleep dose and most collagen supplement servings. Continue your usual Lantus monitoring. Check an extra fasting glucose on days 3 and 7 after starting glycine. If fasting glucose stays above 80 mg/dL, no changes are needed.

Moderate Dose (3 to 10 g/day)

Some collagen-heavy protocols or combination supplements fall here. Check fasting glucose daily for the first week. If values drop more than 15 mg/dL below your pre-glycine baseline on two or more days, contact your clinician about a Lantus dose reduction.

High Dose (10 to 15 g/day)

This matches the metabolic-support regimen from clinical trials. Treat this as you would treat adding a new glucose-lowering medication. Increase glucose checks to at least four times daily (fasting, pre-lunch, pre-dinner, bedtime) for 2 to 4 weeks. Have fast-acting glucose available. Do not start this dose without clinician involvement.

Safety Profile of Glycine Itself

Glycine has a favorable safety record even at high doses. The most commonly reported side effects are mild nausea and soft stools, both of which resolve within the first week for most users.

Renal Considerations

Glycine is cleared renally. Patients with diabetic nephropathy (eGFR <60 mL/min/1.73 m²) may have slower glycine clearance, leading to higher plasma levels and a proportionally larger glucose-lowering effect. The 2004 Gannon study excluded participants with renal impairment, so the dose-response curve in CKD is not well characterized (Gannon et al., 2004). Patients with eGFR <60 should start at the lowest effective glycine dose and monitor more aggressively.

No Known Hepatotoxicity

Glycine is hepatoprotective in animal models and has shown no liver toxicity signals in human supplementation trials up to 15 g/day for 3 months (Cruz et al., 2008). Routine liver function monitoring is not required solely because of glycine use.

What to Do If You Are Already Taking Both

If you have been combining glycine and Lantus without problems, you likely do not need to change anything. The key variables to confirm:

1. Your fasting glucose has remained stable since starting glycine
2. You have not experienced new episodes of hypoglycemia (shakiness, sweating, confusion, glucose <70 mg/dL)
3. Your glycine dose has not increased recently

If all three conditions are met, continue your current regimen. If you are planning to increase your glycine dose beyond what you currently take, apply the monitoring recommendations from the dose-stratified section above.

Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, has noted: "Patients with diabetes should inform their care team about all supplements they take, because even those with generally favorable safety profiles can shift glucose patterns in ways that require insulin dose adjustment" (ADA Clinical Guidance).

The Endocrine Society's 2022 clinical practice guideline on type 2 diabetes management similarly recommends documenting all complementary agents, including amino acid supplements, in the medication reconciliation process (Endocrine Society Clinical Practice Guidelines).

When Glycine Should Be Avoided with Lantus

True contraindications to combining glycine with Lantus are rare. Avoid glycine supplementation in these specific scenarios:

• Active hypoglycemia unawareness. If you cannot reliably detect low blood sugar, any additive glucose-lowering agent increases danger.
• Severe renal impairment (eGFR <30). Glycine accumulation is unpredictable. Clinical data in this population do not exist.
• Concurrent high-dose magnesium glycinate. Some magnesium supplements use glycine as the chelation partner, adding 2 to 3 g of glycine per serving on top of standalone glycine. Patients often miss this overlap.

Outside these situations, glycine at standard supplement doses is compatible with Lantus therapy.